All terms in NCIT
| Label | Id | Description |
|---|---|---|
| Regeneration | NCIT_C17083 | [Reproduction or reconstitution of a lost or injured part. (NCI)] |
| Monoclonal Antibody CEM-231 | NCIT_C29217 | [A monoclonal antibody directed against carcinoembryonic antigen (CEA) which is expressed by most gastrointestinal carcinomas and by some breast, lung and ovarian carcinomas. (NCI04)] |
| Anti-CEA Antibody | NCIT_C2456 | [Any antibody against the tumor associated antigen carcinoembryonic antigen (CEA; CEACAM5), with potential antineoplastic activity. The CEA antigen is overexpressed in certain types of cancer cells.] |
| Nivolumab | NCIT_C68814 | [A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.] |
| Number of Bone Lesions | NCIT_C132463 | [A measurement of the total number of bone tumors.] |
| GPR39 Gene | NCIT_C20873 | [This gene is involved in G protein-coupled receptor signal transduction and the regulation of growth factor release.] |
| Correct | NCIT_C68815 | [Free from error; especially conforming to fact or truth.] |
| Number of New Bone Lesions | NCIT_C132464 | [A measurement of the total number of bone tumors that have not been previously seen or characterized.] |
| Medical-Surgical Nursing | NCIT_C20874 | [Medical-Surgical Nursing includes the provision of care to individuals who have a known or predicted physiological alteration. Working within an interdisciplinary team and guided by theory and research, medical-surgical nursing practice considers all influences on health status and the related social and behavioral problems arising because of the patient's physiological condition. Medical-surgical nursing is practiced in primary, acute, or long-term nursing care facilities. (from ANCC)] |
| Monoclonal Antibody COL-6 | NCIT_C29219 | [A recombinant immunoglobulin antibody directed against the tumor-associated carcinoembryonic antigen (CEA). CEA is a cell surface glycoprotein expressed at high levels in embryonic and fetal digestive epithelial tissue, breast carcinoma, and squamous cell carcinoma of the head and neck. Except for some reactivity to skin and gastric and colon mucosa, monoclonal antibody COL-6 does not appear to react with normal tissues.] |
| Sensitivity | NCIT_C68816 | [A measure of the minimum change in an input signal that an instrument can detect.] |
| Two or More Persisting New Bone Lesions Indicator | NCIT_C132465 | [An indication as to whether there are two or more bone tumors that have been previously seen or characterized.] |
| Monoclonal Antibody B6.2F(ab')2 | NCIT_C29209 | [A divalent F(ab)2 fragment of the monoclonal antibody (MoAb) B6.2 directed against the tumor-associated glycoprotein (TAG-90) found on the surface of primary and metastatic human mammary tumors.. MoAb B6.2 F(ab)2 fragments are obtained through pepsin digestion. The advantage of using MoAb B6.2 F(ab)2 fragments over whole antibodies is that they have reduced immunogenicity, better penetration of tissues, rapid clearance from the body and that they do not induce precipitation.] |
| Perianesthesia Nursing | NCIT_C20880 | [Nursing care of the patient under anesthesia and in the immediate post-anesthesia period.] |
| Emergency Room Nursing | NCIT_C20881 | [The nursing specialty concerned with the care of patients in the emergency room.] |
| PIK3CA NP_006209.2:p.E542X | NCIT_C107480 | [A change in the amino acid residue at position 542 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein where glutamic acid has been replaced by another amino acid.] |
| PIK3CA Protein Variant | NCIT_C98460 | [A variation in the amino acid sequence for the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein.] |
| PIK3CA NP_006209.2:p.E545X | NCIT_C107481 | [A change in the amino acid residue at position 545 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein where glutamic acid has been replaced by another amino acid.] |
| PIK3CA NP_006209.2:p.H1047X | NCIT_C107482 | [A change in the amino acid residue at position 1047 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein where histidine has been replaced by another amino acid.] |
| NRAS NP_002515.1:p.G12X | NCIT_C107483 | [A change in the amino acid residue at position 12 in the GTPase NRas protein where glycine has been replaced by another amino acid.] |